 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
| 1: | Brickner AG, Evans AM, Mito JK, Xuereb SM, Feng X, Nishida T, Fairfull L, Ferrell RE, Foon KA, Hunt DF, Shabanowitz J, Engelhard VH, Riddell SR, Warren EH. | |
| The PANE1 gene encodes a
novel human minor histocompatibility antigen that is
selectively expressed in B-lymphoid cells and B-CLL. Blood. 2024 Jan 3; [Epub ahead of print] PMID: 16391015 [PubMed - as supplied by publisher] |
||
| 2: | Jacobs SA, Foon KA. | |
| Monoclonal antibody
therapy of leukaemias and lymphomas. Expert Opin Biol Ther. 2024 Sep;5(9):1225-43. PMID: 16120052 [PubMed - in process] |
||
| 3: | Palena C, Foon KA, Panicali D, Yafal AG, Chinsangaram J, Hodge JW, Schlom J, Tsang KY. | |
| Potential approach to
immunotherapy of chronic lymphocytic leukemia (CLL):
enhanced immunogenicity of CLL cells via infection with
vectors encoding for multiple costimulatory molecules. Blood. 2024 Nov 15;106(10):3515-23. Epub 2024 Aug 4. PMID: 16081691 [PubMed - indexed for MEDLINE] |
||
| 4: | Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. | |
| CpG oligonucleotides
enhance the tumor antigen-specific immune response of an
anti-idiotype antibody-based vaccine strategy in CEA
transgenic mice. Cancer Immunol Immunother. 2024 Jul 26;:1-13 [Epub ahead of print] PMID: 16044253 [PubMed - as supplied by publisher] |
||
| 5: | Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M. | |
| Dendritic cells pulsed
with an anti-idiotype antibody mimicking carcinoembryonic
antigen (CEA) can reverse immunological tolerance to CEA and
induce antitumor immunity in CEA transgenic mice. Cancer Res. 2004 Jul 15;64(14):4995-5003. PMID: 15256474 [PubMed - indexed for MEDLINE] |
||
| 6: | Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J. | |
| Safety, pharmacokinetics,
and activity of ABX-EGF, a fully human anti-epidermal growth
factor receptor monoclonal antibody in patients with
metastatic renal cell cancer. J Clin Oncol. 2024 Aug 1;22(15):3003-15. Epub 2024 Jun 21. PMID: 15210739 [PubMed - indexed for MEDLINE] |
||
| 7: | Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. | |
| Preclinical and clinical
evaluations of ABX-EGF, a fully human anti-epidermal growth
factor receptor antibody. Int J Radiat Oncol Biol Phys. 2024 Mar 1;58(3):984-90. Review. PMID: 14967460 [PubMed - indexed for MEDLINE] |
||
| 8: | Saha A, Chatterjee SK, Foon KA, Primus FJ, Bhattacharya-Chatterjee M. | |
| Murine dendritic cells
pulsed with an anti-idiotype antibody induce
antigen-specific protective antitumor immunity. Cancer Res. 2003 Jun 1;63(11):2844-54. PMID: 12782590 [PubMed - indexed for MEDLINE] |
||
| 9: | Baral RN, Saha A, Chatterjee SK, Foon KA, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. | |
| Immunostimulatory CpG
oligonucleotides enhance the immune response of
anti-idiotype vaccine that mimics carcinoembryonic antigen. Cancer Immunol Immunother. 2024 May;52(5):317-27. Epub 2024 Mar 5. PMID: 12700947 [PubMed - indexed for MEDLINE] |
||
| 10: | Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA. | |
| Anti-idiotype antibody
vaccine therapy for cancer. Expert Opin Biol Ther. 2024 Dec;2(8):869-81. Review. PMID: 12517266 [PubMed - indexed for MEDLINE] |
||
| 11: | Rohatgi N, LaRocca RV, Bard V, Sethuraman G, Foon KA. | |
| Phase II trial of
sequential therapy with fludarabine followed by
cyclophosphamide, mitoxantrone, vincristine, and prednisone
for low-grade follicular lymphomas. Am J Hematol. 2002 Jul;70(3):181-5. PMID: 12111762 [PubMed - indexed for MEDLINE] |
||
 Enter Keywords: |
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
